BioCurex, Inc.
OTC Bulletin Board : BOCX

BioCurex, Inc.

October 15, 2008 08:30 ET

BioCurex Update Following the 2008 ISOBM Congress. RECAF Triggers Interest for Multiple Collaborations

RICHMOND, BRITISH COLUMBIA--(Marketwire - Oct. 15, 2008) - BioCurex Inc. (OTCBB:BOCX) - wishes to update its shareholders on its participation in the international annual meeting of the International Society for Oncology and Bio-Markers (ISOBM).

The Company was represented by Dr. Moro, who did two presentations: One related to the advent of its new RECAF-ELISA, the most popular format for immunoassays in most clinical and research laboratories. In the other presentation, Dr. Moro overviewed the RECAF cancer marker biology and presented results obtained in the Company's lab as well as from collaborations with other laboratories. The presentation focused on gastrointestinal cancers and it included results obtained with radio-immunoassay (RIA), chemiluminescence (CIA) and enzyme-immunoassay (ELISA). The recently announced results obtained with saliva samples triggered the interest of the session participants.

As a result, scientists from seven centers located in the USA, Europe, Japan or Israel have proposed, agreed, or have expressed an interest in carrying out collaborations with BioCurex.

The Company has previously engaged in collaborative work with three of these laboratories and the results have been published or presented at other congresses. The conversations with scientists from these groups centered on future work using the RECAF-ELISA format.

Three other collaborations relate to the validation and systematic study of RECAF on serum samples and a fourth one is focused on tumor imaging using anti-RECAF antibodies. The feasibility of these collaborations is not the same for all of them and two might require securing funds to carry out the work before starting.

In addition to these collaborations, Dr. Moro discussed its RECAF cancer marker potential uses with representatives from other companies present at the event.

Finally, following the presentations, Dr. Moro was invited to present results on RECAF at another international symposium on cancer markers to be held in Barcelona, in February next year.

To find more about the 2008 ISOBM meeting, go to http://isobm08.umin.jp/index.html

About BioCurex:

BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAF™, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.

BioCurex has signed licensing agreements for its cancer detection blood tests with Abbott Laboratories and with Inverness Medical Innovations.

The cancer marker RECAF™ has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others.

To read more about BioCurex, please visit the News section in our web site (www.biocurex.com).

Note:

The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.

Contact Information